{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fraile-Ribot PA"],"funding":["Ministerio de Economía, Industria y Competitividad, Gobierno de España"],"pagination":["e0098621"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8370190"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["65(9)"],"pubmed_abstract":["The mechanisms underlying an <i>in vivo</i> switch in the resistance phenotype of P. aeruginosa after ceftazidime-avibactam treatment was investigated. The initial isolate (a blood culture) was resistant to meropenem but remained susceptible to antipseudomonal cephalosporins and combinations with β-lactamase inhibitors. One week after ceftazidime-avibactam therapy, a subsequent isolate (a rectal swab) recovered from the same patient showed the opposite phenotype. Whole-genome sequence analysis revealed a single SNP difference between both (ST235) isolates, leading to a P162S change in <i>bla</i><sub>GES-5</sub>, creating <i>bla</i><sub>GES-15</sub>. Thus, <i>bla</i><sub>GES-1</sub>, <i>bla</i><sub>GES-5</sub>, and <i>bla</i><sub>GES-15</sub> were cloned and expressed in the wild-type strai"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["<i>In Vivo</i> Evolution of GES β-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections."],"pmcid":["PMC8370190"],"funding_grant_id":["RD16/0016","PI18/00076","PI21/00017"],"pubmed_authors":["Oliver A","Mulet X","Fernandez J","Gomis-Font MA","Forcelledo L","Lopez-Causape C","Fraile-Ribot PA"],"additional_accession":[]},"is_claimable":false,"name":"<i>In Vivo</i> Evolution of GES β-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections.","description":"The mechanisms underlying an <i>in vivo</i> switch in the resistance phenotype of P. aeruginosa after ceftazidime-avibactam treatment was investigated. The initial isolate (a blood culture) was resistant to meropenem but remained susceptible to antipseudomonal cephalosporins and combinations with β-lactamase inhibitors. One week after ceftazidime-avibactam therapy, a subsequent isolate (a rectal swab) recovered from the same patient showed the opposite phenotype. Whole-genome sequence analysis revealed a single SNP difference between both (ST235) isolates, leading to a P162S change in <i>bla</i><sub>GES-5</sub>, creating <i>bla</i><sub>GES-15</sub>. Thus, <i>bla</i><sub>GES-1</sub>, <i>bla</i><sub>GES-5</sub>, and <i>bla</i><sub>GES-15</sub> were cloned and expressed in the wild-type strai","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-22T09:57:23.19Z","creation":"2025-04-05T23:23:17.013Z"},"accession":"S-EPMC8370190","cross_references":{"pubmed":["34125593"],"doi":["10.1128/aac.00986-21","10.1128/AAC.00986-21"]}}